Newborn Screening in Turkey

As part of a clinical study, around 1000 newborns were investigated for congenital metabolic diseases using NMR in 15 study centers.

Download brochure

Download flyer

Newborn Screening in Turkey

INFAI and Bruker BioSpin are currently conducting a pilot study to establish NMR spectroscopy in the screening of newborns for inborn errors of metabolism. Congenital metabolic disorders occur in 1 in 1500 newborns in Central Europe and in 1 in 500 in Turkey. Urine samples from 1,000 healthy newborn babies from Turkey were collected on their third day of life at 15 study centers in eight Turkish cities (see map). Data from healthy newborns are essential to establish a statistical basis to separate children suffering from congenital metabolic disorders from the statistical model of normality and to avoid possible wrong diagnosis.
NMR-Based Screening for Inborn Errors of Metabolism: Initial Results from a Study on Turkish Neonates, JIMD Reports 2014, 16, 101-111

Further information poster (2011)

Further information poster (2013)